FindTrial
Sign In

Survey on Lung Cancer Patient' Experience and Awareness of Precision Medicine

Survey on Lung Cancer Patients' Experience and Awareness of Precision Medicine - Survey on Lung Cancer Patients' Experience and Awareness of Precision Medicine

Status
Active, not recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000048933
Enrollment
200
Registered
2022-09-26
Start date
2022-10-11
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Cancer

Interventions

None listed

Sponsors

Medical Affairs, Japan Oncology Business Uni, Takeda Pharmaceutical Company Limited.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1.Patients aged 18 years or older with NSCLC 2.Current or previous drug therapy (not indicate for curative surgery or radiation therapy) 3.Agree to complete the questionnaires

Exclusion criteria

Exclusion criteria: 1.Unable to complete questionnaires 2.Provide inadequate response (Outliers of quantity data, inconsistent responses, unmotivated responses, etc.)

Design outcomes

Primary

MeasureTime frame
Responses to questions on opportunities to receive personalized medicine.—

Secondary

MeasureTime frame
Responses to questions on understanding and recognition among lung cancer patients regarding lung cancer treatment and lung cancer-related genetic testing.—

Countries

Japan

Contacts

Public ContactRyoichi Tsubouchi

Takeda Pharmaceutical Company Limited. Medical Affairs, Japan Oncology Business Unit

japan.oncology.iir.office@takeda.com03-3278-2111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026